Phase 2 AL Amyloidosis Clinical Trials

9 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 19 of 9 trials

Recruiting
Phase 2

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

AL Amyloidosis
European Myeloma Network B.V.30 enrolled10 locationsNCT06649695
Recruiting
Phase 2

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

AL Amyloidosis
Mayo Clinic96 enrolled2 locationsNCT05898646
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting
Phase 1Phase 2

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

AL Amyloidosis
Brigham and Women's Hospital49 enrolled1 locationNCT06569147
Recruiting
Phase 1Phase 2

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AmyloidosisAL Amyloidosis
University of Texas Southwestern Medical Center37 enrolled3 locationsNCT05145816
Recruiting
Phase 2

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

AL Amyloidosis
Peking Union Medical College Hospital35 enrolled1 locationNCT07079423
Recruiting
Phase 1Phase 2

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis
Rajshekhar Chakraborty, MD53 enrolled4 locationsNCT05451771
Recruiting
Phase 2

Teclistamab in Previously Treated AL Amyloidosis

AL Amyloidosis
Peking Union Medical College Hospital30 enrolled1 locationNCT06935162
Recruiting
Phase 2

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Renal AL Amyloidosis
Barbara Ann Karmanos Cancer Institute20 enrolled1 locationNCT06420167